Page URL:

NHS England sets out personalised medicine strategy

28 September 2015
Appeared in BioNews 821

NHS England's national medical director, Sir Bruce Keogh, has outlined how the organisation's approach to personalised medicine will develop over the coming years and expand beyond the work of the 100,000 Genomes Project (100KGP).

The strategy aims that, instead of treating patients on the basis of a set of symptoms, doctors will increasingly use emerging diagnostic technologies and genomics to detect the underlying causes of disease. By targeting interventions to the patients most likely to respond, the strategy is intended to lead to more effective and efficient treatment.

It also involves a greater role for preventive medicine, with the hope that diseases can be predicted and prevented, or else detected years earlier than they would be currently.

In a paper to the Board, Sir Bruce said that moving away from a 'one size fits all' approach to treatment would allow NHS England to become efficient and improve patient outcomes.

'Adopting a personalised medicine approach will allow the most appropriate intervention for the individual to be used, reducing costs and preventing adverse reactions in those who will not respond to certain treatments,' he writes.

'Given the current NHS drugs budget is over £12 billion, using diagnostics to guide treatment interventions is of fundamental importance to NHS England as a commissioning organisation.'

Proposals for implementation include developing the infrastructure of the NHS, including a national network of genomic testing laboratories emerging from the 100KGP, and greater harnessing of technology.

Professor Sue Hill, chief scientific officer, says that the integration of diagnostic, therapeutic and genetic data will also be essential.

'The NHS carries out more than a billion diagnostic tests every year, but we are only just learning the potential of all this information coming together to form an integrated picture over time – particularly when coupled with genomic sequence data,' she writes.

Professor Hill added: 'By taking a strategic approach to developing a more personalised approach to medicine, building on the learning coming through from NHS Genomic Medicine Centres, this country will be one of the most scientifically advanced in the world in use of genomics.'

However, Dr Stuart Hogarth, a senior research fellow from King's College London, said that while reorganisation of infrastructure to improve the quality of molecular diagnostic testing in the NHS 'seems very sensible' some of the plans may be ahead of the science.

'The very bold claims being made are not supported by many concrete examples,' Dr Hogarth told BioNews. 'We still have very few targeted therapies where the target population is defined using a companion diagnostic, and they are nearly all cancer drugs. Given that the front-line therapies in cancer are still surgery and radiotherapy, this is hardly a revolution in medicine.'

He also said that some of the assumptions made in the paper, such as that preventive therapy will be 'low cost', may not be a given.

'The same can be said for the promise of earlier detection – a laudable aim, but experience has taught us that screening needs to be rigorously evaluated to ensure that the benefits outweigh the harms,' he said.

NHS England will next be developing a five-year work programme, an investment plan and a review of potential cost savings and efficiency gains to be presented to the Board.

Board Paper
NHS England [pdf] |  24 September 2015
10 July 2017 - by Jen Willows 
The Chief Medical Officer of England's annual report has recommended that personalised medicine approaches be adopted widely within the NHS.
10 July 2017 - by Dr Rachel Montgomery 
A packed public event, produced by the Progress Educational Trust in partnership with Genomics England, saw the Chief Medical Officer for England launch her report 'Generation Genome'...
19 September 2016 - by Rhys Baker 
Personalised Medicine. A promise of medical treatment tailored to the individual. A promise that has been decades in the delivery. But now, as such treatment appears to be within reach, will the dream be dashed by bureaucracy, inertia and funding crises?...
13 June 2016 - by Rachel Reeves 
Genetic sequencing leading to targeted treatment significantly improves cancer patient outcomes in early-stage clinical trials, according to a study...
4 April 2016 - by Dr James Heather 
Hospitals around the UK are going to start examining the DNA of tumour cells from paediatric cancer patients in a pilot study starting later this year...
24 August 2015 - by Kirsty Oswald 
Researchers have shown that a skin cancer drug can be used to treat advanced lung cancer in patients whose tumours harbour a particular mutation...
13 April 2015 - by Dr Nicoletta Charolidi 
A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour antibodies has shown early signs of promise...
16 March 2015 - by Dr Hannah Somers 
Three British men have been diagnosed with rare diseases after having their complete genomes sequenced as part of the UK-based 100,000 Genomes Project...
9 February 2015 - by Dr Nicola Davis 
The US President, Barack Obama, has revealed details of a multi-agency personalised medicine research plan...
29 September 2014 - by Siobhan Chan 
UK researchers have identified the most serious genetic mutations responsible for a rare condition that causes blindness, opening the door for personalised treatment and tailored gene therapies...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.